1. Zhou YP#, Wei YP#, Yang YJ, Xu XQ, Wu T, Liu C, Mei KY, Peng FH, Wang HP, Sun K, Li JY, Wang HF, Li MT, Wang DL, Miao Q, Jiang X*, Jing ZC*. Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension. J Am Coll Cardiol. 2022 Apr 19;79(15):1477-1488. (IF = 27.203)
2. Jiang X#, Zhou YJ#,Zhou YP#, Peng FH, Wang L, Ma W, Cao YS, Pan X, Zhang GC, Zhang F, Fan FL, Wu BX, Huang W, Yang ZW, Hong C, Li MT, Wang YN, Xu XQ, Wang DL, Zhang SY, Jing ZC*. Clinical features and survival in Taksyasu's arteritis-associated pulmonary hypertension: a nationwide study. Eur Heart J. 2021 Sep 10. (IF = 29.983)
3. Yan Y#, He YY#, Jiang X#, Wang Y, Chen JW, Zhao JH, Ye J, Lian TY, Zhang X, Zhang RJ, Lu D, Guo SS, Xu XQ, Sun K, Li SQ, Zhang LF, Zhang X, Zhang SY, Jing ZC*. DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension. Sci Adv. 2020 Dec 9;6(50). (IF = 14.136)
4. He YY#, Yan Y#, Jiang X, Zhao JH, Wang Z, Wu T, Wang Y, Guo SS, Ye J, Lian TY, Xu XQ, Zhang JL, Sun K, Peng FH, Zhou YP, Mao YM, Zhang X, Chen JW, Zhang SY, Jing ZC*, Spermine promotes pulmonary vascular remodeling and its synthase is a therapeutic target for pulmonary arterial hypertension. Eur Respir J. 2020 Nov 5;56(5):2000522. doi: 10.1183/13993003.00522-2020. (IF = 16.671)
5. Wang XJ#, Xu XQ#, Sun K#, Liu KQ, Li SQ, Jiang X, Zhao QH, Wang L, Peng FH, Ye J, Wu Y, Jiang R, Zhang J, Huang W, Bei WB, Yan Y, Li JH, Liu QQ, Li S, Wang Y, Zhang SY, Zhang X, Jing ZC*. Association of rare PTGIS variants with susceptibility and pulmonary vascular response in patients with idiopathic pulmonary arterial hypertension. JAMA Cardiol. 2020 Apr 1; 5(6): 677-684. (IF=14.676, R)
6. Wang XJ#, Lian TY#, Jiang X, Liu SF, Li SQ, Jiang R, Wu WH, Ye J, Cheng CY, Du Y, Xu XQ, Wu Y, Peng FH, Sun K, Mao YM, Yu H, Liang C, John YJ, Zhang SY, Zhang X, Jing ZC*. Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension. Eur Respir J. 2019 Mar 14;53(3):1801609. doi: 10.1183/13993003.01609-2018. (IF=12.399, R)
7. Jing ZC#*, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Arneson C, Laliberte K, and Rubin LJ. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized controlled trial. Circulation.2013 Feb 5;127(5):624-633. (IF=14.948, C100, F1000, PIII)
8. Jing ZC#*, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, Pan L, Zhang ZL, Liu XQ, Zhang YS, Jiang X, Galiè Nfor the Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study. Vadenafil in Pulmonary Arterial Hypertension: A Randomized, Double-blind, Placebo-controlled Study.Am J Respir Crit Care Med. 2011, 183(12):1723-1729. (IF=11.080, R, PIII)
9. Jing ZC#*, Jing X#, Han ZY#, Xu XQ, Wang Y, Wu Y, Lv H, Ma CR, Yang YJ, Pu JL. Iloprost for Pulmonary Vasodilator Testing in Idiopathic Pulmonary Arterial Hypertension. Eur Respir J. 2009 Jun;33:1354-1360. (IF=5.527, R)
10. Jing ZC#, Xu XQ#, Han ZY#, Wu Y, Deng KW, Wang H, Wang ZW, Cheng XS, Xu B, Hu SS,Hui RT, Yang YJ. Registry and survival study of Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007 Aug;132:373-379. (IF=4.143, C100,F1000)